Lilly's Lung Cancer Drug Portrazza OK'd

25 Nov 2015

• By Donna Young

The FDA on Nov. 24 gave Eli Lilly and Co. the go-ahead to market Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL) in combination with gemcitabine and cisplatin in the US for patients with metastatic squamous non-small-cell lung cancer (NSCLC) – the first biologic available as a first-line therapy for the very difficult-to-treat disease, which has only a five-year survival rate.

"This is a complex disease and there is an urgent need for effective, first-line treatments," said Richard Gaynor, senior vice...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

ASCO: Pushing The Frontiers Of ADCs

19 Jun 2025

• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

17 Jun 2025

• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.

Enliven Raises $230m To Fund Scemblix Leukemia Challenger

17 Jun 2025

• By Andrew McConaghie

The company believes its drug could eventually displace Novartis’s Scemblix in first-line chronic myeloid leukemia treatment, but for now is preparing for a second-/third-line pivotal study.

BMS’s Breyanzi Stands To Further Expand Broad Lymphoma Coverage

16 Jun 2025

• By Alaric DeArment

The drugmaker presented data at a lymphoma meeting showing strong efficacy for the CAR-T in marginal zone lymphoma, the second most common indolent lymphoma.